Medical Database

Dear Valued Client,

We are pleased to announce a major update to the LDSRx® Interpretation Software, enhancing its capability to link antibiotic resistance (ABR) genes directly to their corresponding microorganisms (pathogens) detected in patient samples.
This improvement ensures that every ABR gene identified through molecular testing is now mapped and reported alongside its associated pathogen(s) in LDSRx reports (see attached example, page 3). This enhancement provides clinicians and laboratorians with clearer insights into the origin and clinical relevance of resistance markers, enabling more effective treatment decisions, infection tracking, and antimicrobial stewardship.
Importantly, this update also fulfills the College of American Pathologists (CAP) checklist requirement MIC.65630, which specifies that detection of genotypic antimicrobial resistance markers must be linked or attributed to a corresponding organism when testing is performed directly on patient specimens (e.g., urine, respiratory samples, or blood culture broth).
By correlating ABR genes with compatible organisms, LDSRx ensures that your reports meet CAP compliance standards and maintain the highest level of compliance and reporting accuracy.
As always, our goal is to continue providing our partner laboratories and healthcare providers with advanced tools that improve diagnostic accuracy, patient care, and regulatory compliance.
For additional information or technical support regarding this update, please contact our support team at support@medicaldatabase.com .

Thank you for your continued trust in LDSRx and Medical Database.

Best regards,

Dr. Safedin Sajo Beqaj, PhD
President & CEO, Medical Database, Inc.
sajo@medicaldatabase.com
+1 847-769-3701